Findings from CARTITUDE-1 found that ciltacabtagene autoleucel (cilta-cel), an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy for multiple myeloma, achieved high response rates and durable responses in patients with relapsed/refractory disease. After 18 months, 80% of patients achieved a complete response to treatment and the rate of progression-free survival was 66%.
